Recently, the results of the large-scale, multicenter ambispective cohort study (FLYING study) on Fulaimei (PEG-Loxenatide Injection), a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA) of Hansoh Pharmaceutical, were published in the internationally renowned medical journal MedComm (IF: 10.7) [1]. This study confirmed that long-term use of Fulaimei in patients with type 2 diabetes mellitus (T2DM) significantly reduces the risk of major adverse cardiovascular events (MACE) by 32%.
The FLYING study is the world's first large-scale real-world study to assess the cardiovascular benefits of GLP-1RA specifically in the Chinese population, its findings provide robust evidence to support Fulaimei’s significant cardiovascular advantages for T2DM patients.
Managing cardiovascular complications and related mortality has always been a major challenge in diabetes treatment. This FLYING study was conducted across six tertiary hospitals in three cities in China. A large-language model was used for retrospective screening, and a total of over 12,000 patients with T2DM, all of whom had pre-existing cardiovascular diseases or cardiovascular risk factors, were included.
The study compared cardiovascular event rates over a four-year follow-up period between the Fulaimei treated group (treatment group) and the non-incretin antidiabetic drugs treated group (control group).
The results demonstrated that the risk of major adverse cardiovascular events in the Fulaimei trated group was 32% lower than that in the control group, and the incidences of first non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death were all significantly lower than those in the control group [1].
The FLYING study is the first to provide compelling evidence that Fulaimei not only helps lower blood sugar level but also reduces the risk of adverse cardiovascular events. It provides a superior option for the long-term treatment of T2DM who have cardiovascular diseases or cardiovascular risk factors. Its significant cardiovascular benefits can contribute to the improvement of patient quality of life, reduced additional healthcare costs, and extended survival.
References: [1]MedComm (2020) . 2025 Feb 13;6(2):e70094.
(Source of image materials: The website of MedComm）
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
